Ultragenyx Pharmaceutical Inc. Income Statement
RARE / Health Care|14 years of annual SEC 10-K data (FY2012-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 14 fiscal years. All figures from audited SEC 10-K filings.
Ultragenyx Pharmaceutical Inc. reported $673M in revenue and $575M in net loss for FY2025. Revenue has grown at a 224.2% compound annual rate over the past 9 years.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -2.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M | $103.7M | $51.5M | $2.6M | $51.5M | $133.0K | $17.0K | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | $1.1M | $1.0K | - | - | - | - | - |
| SG&A Expense | $349.0M | $321.0M | $310.0M | $278.1M | $161.5M | $127.7M | $99.9M | $127.7M | $33.0M | $10.8M | $33.0M | $10.8M | $4.5M | $3.3M |
| R&D Expense | $750.0M | $698.0M | $648.0M | $705.8M | $357.4M | $294.0M | $231.6M | $294.0M | $114.7M | $46.0M | $114.7M | $46.0M | $27.8M | $12.6M |
| Operating Income | -$535.0M | -$536.0M | -$569.0M | -$648.9M | -$424.2M | -$371.4M | -$328.9M | -$371.4M | -$147.7M | -$56.8M | -$147.7M | -$56.8M | -$32.3M | -$16.0M |
| Income Tax | $4.0M | $2.0M | -$2.0M | $5.7M | $3.3M | $514.0K | -$16.2M | $514.0K | $35.0K | $35.0K | $0 | $0 | $0 | - |
| Net Income | -$575.0M | -$569.0M | -$607.0M | -$707.4M | -$402.7M | -$197.6M | -$302.1M | -$197.6M | -$145.6M | -$59.8M | -$145.6M | -$59.8M | -$35.1M | -$16.3M |
| EPS (Basic) | -$8.25 | -$10.12 | -$6.70 | -$3.07 | - | $0.42 | - | $0.63 | - | - | - | - | - | - |
| EPS (Diluted) | -$8.25 | -$10.12 | -$6.70 | -$3.07 | -$7.12 | $0.41 | -$7.12 | $0.62 | -$3.96 | -$2.25 | - | - | - | - |
| Shares Outstanding | 92.5M | 82.3M | 70.2M | 69.3M | 66.8M | 57.8M | 50.9M | 44.2M | 41.2M | 38.9M | 36.8M | 28.8M | 3.4M | 1.4M |
| Operating Margin | -79.5% | -95.7% | -131.1% | -178.6% | -409.0% | -721.2% | -12593.5% | -721.2% | -111081.2% | -333988.2% | - | - | - | - |
| Profit Margin | -85.4% | -101.6% | -139.9% | -194.7% | -388.3% | -383.8% | -11567.3% | -383.8% | -109487.2% | -351776.5% | - | - | - | - |